论文部分内容阅读
胰岛素是糖尿病患者常用的降糖药物,但胰岛素药效短,即使长效胰岛素也不能达到令人满意的效果。成纤维细胞生长因子(FGF)-21是近期发现的一种不依赖于胰岛素但具有降糖作用的潜力型药物。通过检测mFGF-21治疗后2型糖尿病db/db小鼠血糖和糖基化血红蛋白的变化,研究其对2型糖尿病动物是否有长期、稳定的降糖效果。一天一次治疗模型动物结果表明,mFGF-21可以有效地将模型动物血糖调控在正常水平,维持至少24 h,并且随着mFGF-21剂量的增加对血糖的调控机制更加快速、持久。两天注射一次mFGF-21,虽然模型动物血糖下降缓慢,但是长期治疗后仍能降至正常水平,在停止给药后24 h之内其血糖仍能稳定维持在正常水平;其糖基化血红蛋白水平与胰岛素阳性对照组相比显著下降。结果提示,FGF-21有望成为能够替代胰岛素的长效的降糖药物。
Insulin is commonly used in patients with diabetes hypoglycemic drugs, but the short-acting insulin, even the long-acting insulin can not achieve satisfactory results. Fibroblast growth factor (FGF) -21 is a recently discovered potential insulin-independent but hypoglycemic drug. By detecting the changes of blood glucose and glycosylated hemoglobin in type 2 diabetic db / db mice after mFGF-21 treatment, we investigated whether it has long-term and stable hypoglycemic effect on type 2 diabetic animal. The animal model of once-daily treatment showed that mFGF-21 can effectively regulate blood glucose levels of model animals at normal levels for at least 24 h, and that the regulatory mechanism of blood glucose is more rapid and longer with the increase of mFGF-21 dosage. The two-day injection of mFGF-21, although the model animals blood glucose decreased slowly, but after long-term treatment can still be reduced to normal levels within 24 hours after stopping the administration of blood glucose remained stable at normal levels; its glycosylated hemoglobin The level of insulin-positive control group decreased significantly. The results suggest that FGF-21 is expected to become a long-acting hypoglycemic agent that can replace insulin.